[go: up one dir, main page]

AR115015A1 - Derivados de azaespiro piperazina - Google Patents

Derivados de azaespiro piperazina

Info

Publication number
AR115015A1
AR115015A1 ARP190100746A ARP190100746A AR115015A1 AR 115015 A1 AR115015 A1 AR 115015A1 AR P190100746 A ARP190100746 A AR P190100746A AR P190100746 A ARP190100746 A AR P190100746A AR 115015 A1 AR115015 A1 AR 115015A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
members
heterocycloalkyl
heteroaryl
Prior art date
Application number
ARP190100746A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR115015A1 publication Critical patent/AR115015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La presente proporciona, en parte, compuestos de fórmula (1), o un N-óxido del mismo, o una sal farmacéuticamente aceptable del compuesto o el N-óxido, en donde: X¹, X², R¹, R², m y n son como se describe en la presente; procesos para la preparación de; intermediarios usados en la preparación de; y composiciones que contienen dichos compuestos, N-óxidos o sales, y sus usos para tratar trastornos mediados por M4 (o asociados con M4) que incluyen, por ejemplo, enfermedad de Alzheimer, enfermedad de Parkinson, esquizofrenia (por ejemplo, sus síntomas cognitivos y negativos), dolor, adicción y un trastorno del sueño. Reivindicación 1: Un compuesto de fórmula (1), o un N-óxido del mismo, o una sal farmacéuticamente aceptable del compuesto o el N-óxido, en donde: X¹ y X² son cada uno independientemente CH o nitrógeno, siempre y cuando X¹ y X² no sean ambos CH; R¹ se selecciona del grupo que consiste en halógeno, ciano, hidroxi, -SF₅, nitro, -N(R⁶)(R⁷), C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ alquiltio, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, -O-heterocicloalquilo (4 a 6 miembros), C₆₋₁₀ arilo, heteroarilo (5 a 10 miembros) y heterocicloalquilo (4 a 8 miembros), en donde dicho C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ alquiltio, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, -O-heterocicloalquilo (4 a 6 miembros), C₆₋₁₀ arilo, heteroarilo (5 a 10 miembros) y heterocicloalquilo (4 a 8 miembros) están opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados del grupo que consiste en halógeno, ciano, hidroxi, -N(R⁶)(R⁷), C₁₋₆ alquilo, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, y heteroarilo (5 a 6 miembros), en donde dicho C₁₋₆ alquilo, C₁₋₆ alcoxi, y heteroarilo (5 a 6 miembros) están opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados del grupo que consiste en halógeno, ciano, hidroxi, C₁₋₆ alquilo y C₁₋₆ alcoxi; R² se selecciona del grupo que consiste en hidrógeno, halógeno, ciano, hidroxi, -SF₅, nitro, -N(R⁶)(R⁷), C₁₋₆ alquilo, y C₁₋₆ alcoxi, en donde dicho C₁₋₆ alquilo y C₁₋₆ alcoxi están opcionalmente sustituidos con 1 a 3 halógenos; R⁶ y R⁷ se seleccionan, cada uno independientemente, de hidrógeno, C₁₋₆ alquilo o C(O)-CH₃; m es 1 ó 2; y n es 1 ó 2.
ARP190100746A 2018-03-23 2019-03-25 Derivados de azaespiro piperazina AR115015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862647106P 2018-03-23 2018-03-23

Publications (1)

Publication Number Publication Date
AR115015A1 true AR115015A1 (es) 2020-11-18

Family

ID=66102243

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100746A AR115015A1 (es) 2018-03-23 2019-03-25 Derivados de azaespiro piperazina

Country Status (14)

Country Link
US (2) US11524954B2 (es)
EP (2) EP4219464A1 (es)
JP (2) JP7497294B2 (es)
CN (1) CN112154145B (es)
AR (1) AR115015A1 (es)
CA (1) CA3094366A1 (es)
DK (1) DK3768669T3 (es)
ES (1) ES2942837T3 (es)
FI (1) FI3768669T3 (es)
HU (1) HUE061533T2 (es)
PL (1) PL3768669T3 (es)
PT (1) PT3768669T (es)
TW (1) TWI801540B (es)
WO (1) WO2019183636A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183636A1 (en) * 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivaves
UY38906A (es) 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
CR20220153A (es) 2019-10-09 2022-05-03 Novartis Ag Derivados de 2–azaespiro [3.4] octano como agonistas de m4
KR20210067005A (ko) * 2019-11-28 2021-06-08 제이투에이치바이오텍 (주) 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도
ES2983860T3 (es) 2019-12-06 2024-10-25 Neurocrine Biosciences Inc Antagonistas del receptor muscarínico 4 y métodos de uso
JP7707176B2 (ja) * 2020-02-05 2025-07-14 ニューロクライン バイオサイエンシーズ，インコーポレイテッド ムスカリン性受容体４アンタゴニストおよび使用方法
WO2022238327A1 (en) 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors
IL310439A (en) * 2021-07-30 2024-03-01 Neurocrine Biosciences Inc Muscarinic receptor 4 antagonists and methods of use
IL319164A (en) * 2022-09-16 2025-04-01 Cerevel Therapeutics Llc M4 actuators/modulators and their uses
KR20250133755A (ko) * 2023-01-12 2025-09-08 세레벨 쎄라퓨틱스, 엘엘씨 M4 활성제/조절제로서의 스피로 유도체 및 이의 용도

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
WO1998044955A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
AU3976402A (en) 2000-11-03 2002-06-03 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
CA2501945A1 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
UY28538A1 (es) * 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
KR20070034524A (ko) 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
EP1899296B1 (en) 2005-06-22 2010-11-17 Pfizer Products Inc. Histamine-3 receptor antagonists
TW200713011A (en) 2005-09-30 2007-04-01 Hon Hai Prec Ind Co Ltd System, method and electrical apparatus for data transferring
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
US20070107917A1 (en) 2005-11-14 2007-05-17 Doherty Brian J Multifunctional robot tool
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
BRPI0806473A2 (pt) 2007-01-22 2011-09-27 Pfizer Prod Inc sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo
WO2012047702A1 (en) 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
EP4413985A3 (en) 2014-02-06 2024-10-23 Nxera Pharma UK Limited Pharmaceutical compounds
CN106413623B (zh) 2014-03-21 2020-07-03 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2019183636A1 (en) * 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivaves

Also Published As

Publication number Publication date
PL3768669T3 (pl) 2023-07-03
US12398119B2 (en) 2025-08-26
US20230192654A1 (en) 2023-06-22
CN112154145A (zh) 2020-12-29
EP4219464A1 (en) 2023-08-02
DK3768669T3 (da) 2023-04-24
FI3768669T3 (fi) 2023-04-26
EP3768669B1 (en) 2023-01-25
JP2024037979A (ja) 2024-03-19
CN112154145B (zh) 2023-10-17
EP3768669A1 (en) 2021-01-27
JP2021519269A (ja) 2021-08-10
JP7497294B2 (ja) 2024-06-10
WO2019183636A1 (en) 2019-09-26
CA3094366A1 (en) 2019-09-26
US20210024497A1 (en) 2021-01-28
PT3768669T (pt) 2023-04-24
ES2942837T3 (es) 2023-06-07
TWI801540B (zh) 2023-05-11
HUE061533T2 (hu) 2023-07-28
US11524954B2 (en) 2022-12-13
TW202003491A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
AR115015A1 (es) Derivados de azaespiro piperazina
UY37311A (es) Derivados de 5,7-dihidro-pirrolo-piridina
AR121661A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20181449A1 (es) Compuestos utiles como inhibidores de cinasa
AR100154A1 (es) Compuesto heterocíclico que contiene nitrógeno
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
BR112015021336A2 (pt) compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR119234A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
AR107928A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
AR085398A1 (es) Ureas asimetricas y usos medicos de las mismas
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
PE20190979A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2

Legal Events

Date Code Title Description
FB Suspension of granting procedure